Login
CN
Why MingCeler
HomeWhy MingCelerClient Case
MingCelerClient Case
-
Aug 21, 2025MingCeler Biotech congratulates its partner Xinya Gene on obtaining the U.S. FDA clinical trial approval for its new DMD cytosine base editing drug, GEN6050X.Xinya Gene recently announced that the Investigational New Drug (IND) application for GEN6050X, its globally first-in-class gene-editing drug for the treatment of Duchenne Muscular Dystrophy (DMD), has been approved by the U.S. Food and Drug Administration (FDA). -
Aug 21, 2025Highly cooperative chimeric super-SOX: Inducing naivepluripotency beyond species boundariesThe research team led by Hans R. Schöler at the Max Planck Institute in Germany, in collaboration with Dr. Wu Guangming from Mingxun Biotechnology and other teams, published a study titled "Highly cooperative chimeric super-SOX: Inducing naive pluripotency beyond species boundaries" in the top-tier academic journal Cell Stem Cell. The paper provides an in-depth exploration of the aforementioned topic, with Dr. Wu Guangming from Mingxun Biotechnology contributing to a detailed analysis.
